Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q4 FY24 results · Jan–Mar 2024
Cohance Lifesciences reported revenue from operations of ₹252.93 crore (down 31.5% from Q4 FY23) and net profit of ₹53.37 crore (down 56.9% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 252.93 | 369.36 | −31.5% | 219.82 | +15.1% |
| Other income | 17.05 | 11.40 | +49.6% | 14.34 | +18.9% |
| Total income | 269.98 | 380.76 | −29.1% | 234.16 | +15.3% |
| Profit before tax | 70.85 | 166.21 | −57.4% | 65.47 | +8.2% |
| Net profit for the period | 53.37 | 123.97 | −56.9% | 46.75 | +14.2% |
| EPS, basic (₹) | 2.10 | 4.87 | −56.9% | 1.84 | +14.0% |
| Net margin (%) | 21.1 | 33.6 | 21.3 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 243.52 | 364.39 | −33.2% | 212.83 | +14.4% |
| Other income | 16.87 | 10.75 | +56.8% | 13.97 | +20.7% |
| Total income | 260.39 | 375.14 | −30.6% | 226.79 | +14.8% |
| Profit before tax | 71.06 | 172.47 | −58.8% | 69.50 | +2.2% |
| Net profit for the period | 53.43 | 130.16 | −58.9% | 52.36 | +2.0% |
| EPS, basic (₹) | 2.10 | 5.11 | −58.9% | 2.06 | +1.9% |
| Net margin (%) | 21.9 | 35.7 | 24.6 |
Consolidated
- Filed with BSE
- 01 Jun 2024, 12:01 IST
- Board meeting
- 30 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Jun 2024, 12:01 IST
- Board meeting
- 30 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE